Mukowiscydoza (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Mukowiscydoza" in Polish language version.

refsWebsite

Global rank Polish rank

12nih.gov

4^th place

7^th place

11doi.org

2^nd place

6^th place

1worldcat.org

5^th place

2^nd place

1web.archive.org

1^st place

1eshre.eu

low place

7,080^th place

1mp.pl

8,738^th place

165^th place

doi.org

dx.doi.org

TeresaT. Collazo TeresaT. i inni, Common mutations in Cuban cystic fibrosis patients, „Journal of Cystic Fibrosis”, 8 (1), 2009, s. 47–49, DOI: 10.1016/j.jcf.2008.09.004, PMID: 18938114 .
E.E. Kerem E.E. i inni, The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508), „The New England Journal of Medicine”, 323 (22), 1990, s. 1517–1522, DOI: 10.1056/NEJM199011293232203, PMID: 2233932 .
T.T. Dörk T.T. i inni, Characterization of a novel 21-kb deletion, CFTRdele2,3(21 kb), in the CFTR gene: a cystic fibrosis mutation of Slavic origin common in Central and East Europe, „Human Genetics”, 106 (3), 2000, s. 259–268, DOI: 10.1007/s004390000246, PMID: 10798353 .
F.G. deF.G. Araújo F.G. deF.G. i inni, Prevalence of deltaF508, G551D, G542X, and R553X mutations among cystic fibrosis patients in the North of Brazil, „Brazilian Journal of Medical and Biological Research”, 38 (1), 2005, s. 11–15, DOI: 10.1590/s0100-879x2005000100003, PMID: 15665983 .
S.E.S.E. Gabriel S.E.S.E. i inni, Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model, „Science”, 266 (5182), 1994, s. 107–109, DOI: 10.1126/science.7524148, PMID: 7524148 .
G.B.G.B. Pier G.B.G.B. i inni, Salmonella typhi uses CFTR to enter intestinal epithelial cells, „Nature”, 393 (6680), 1998, s. 79–82, DOI: 10.1038/30006, PMID: 9590693 .
GuidoG. Modiano GuidoG., Bianca M.B.M. Ciminelli Bianca M.B.M., Pier F.P.F. Pignatti Pier F.P.F., Cystic fibrosis and lactase persistence: a possible correlation, „European Journal of Human Genetics”, 15 (3), 2007, s. 255–259, DOI: 10.1038/sj.ejhg.5201749, PMID: 17180122 .
SamiS. Hraiech SamiS., FabienneF. Brégeon FabienneF., Jean-MarcJ.M. Rolain Jean-MarcJ.M., Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status, „Drug Design, Development and Therapy”, 9, 2015, s. 3653–3663, DOI: 10.2147/DDDT.S53123, PMID: 26213462, PMCID: PMC4509528 .
StephanieS. Trend StephanieS. i inni, The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways, „Journal of Cystic Fibrosis”, 16 (6), 2017, s. 663–670, DOI: 10.1016/j.jcf.2017.06.012, PMID: 28720345 .
MartinaM. Rossitto MartinaM., Ersilia V.E.V. Fiscarelli Ersilia V.E.V., PaolaP. Rosati PaolaP., Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Pseudomonas aeruginosa in Cystic Fibrosis. An Argumentative Review, „Frontiers in Microbiology”, 9, 2018, s. 775, DOI: 10.3389/fmicb.2018.00775, PMID: 29780361, PMCID: PMC5945972 .
StephanieS. Trend StephanieS. i inni, Use of a Primary Epithelial Cell Screening Tool to Investigate Phage Therapy in Cystic Fibrosis, „Frontiers in Pharmacology”, 9, 2018, s. 1330, DOI: 10.3389/fphar.2018.01330, PMID: 30546305, PMCID: PMC6280614 .

eshre.eu

ESHRE: Guidelines for FISH-based PGD. [dostęp 2021-07-05]. [zarchiwizowane z tego adresu (2012-04-02)].

mp.pl

Zasady rozpoznawania i leczenia mukowiscydozy. Stanowisko Polskiej Grupy Roboczej Mukowiscydozy przy Zarządzie Głównym Polskiego Towarzystwa Pediatrycznego (1999). „Medycyna Praktyczna Pediatria”. 3, s. 64–74, 2000.

nih.gov

ncbi.nlm.nih.gov

D.D. Abeliovich D.D. i inni, Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population, „American Journal of Human Genetics”, 51 (5), 1992, s. 951–956, PMID: 1384328, PMCID: PMC1682830 .
TeresaT. Collazo TeresaT. i inni, Common mutations in Cuban cystic fibrosis patients, „Journal of Cystic Fibrosis”, 8 (1), 2009, s. 47–49, DOI: 10.1016/j.jcf.2008.09.004, PMID: 18938114 .
E.E. Kerem E.E. i inni, The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508), „The New England Journal of Medicine”, 323 (22), 1990, s. 1517–1522, DOI: 10.1056/NEJM199011293232203, PMID: 2233932 .
T.T. Dörk T.T. i inni, Characterization of a novel 21-kb deletion, CFTRdele2,3(21 kb), in the CFTR gene: a cystic fibrosis mutation of Slavic origin common in Central and East Europe, „Human Genetics”, 106 (3), 2000, s. 259–268, DOI: 10.1007/s004390000246, PMID: 10798353 .
F.G. deF.G. Araújo F.G. deF.G. i inni, Prevalence of deltaF508, G551D, G542X, and R553X mutations among cystic fibrosis patients in the North of Brazil, „Brazilian Journal of Medical and Biological Research”, 38 (1), 2005, s. 11–15, DOI: 10.1590/s0100-879x2005000100003, PMID: 15665983 .
S.E.S.E. Gabriel S.E.S.E. i inni, Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model, „Science”, 266 (5182), 1994, s. 107–109, DOI: 10.1126/science.7524148, PMID: 7524148 .
G.B.G.B. Pier G.B.G.B. i inni, Salmonella typhi uses CFTR to enter intestinal epithelial cells, „Nature”, 393 (6680), 1998, s. 79–82, DOI: 10.1038/30006, PMID: 9590693 .
GuidoG. Modiano GuidoG., Bianca M.B.M. Ciminelli Bianca M.B.M., Pier F.P.F. Pignatti Pier F.P.F., Cystic fibrosis and lactase persistence: a possible correlation, „European Journal of Human Genetics”, 15 (3), 2007, s. 255–259, DOI: 10.1038/sj.ejhg.5201749, PMID: 17180122 .
SamiS. Hraiech SamiS., FabienneF. Brégeon FabienneF., Jean-MarcJ.M. Rolain Jean-MarcJ.M., Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status, „Drug Design, Development and Therapy”, 9, 2015, s. 3653–3663, DOI: 10.2147/DDDT.S53123, PMID: 26213462, PMCID: PMC4509528 .
StephanieS. Trend StephanieS. i inni, The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways, „Journal of Cystic Fibrosis”, 16 (6), 2017, s. 663–670, DOI: 10.1016/j.jcf.2017.06.012, PMID: 28720345 .
MartinaM. Rossitto MartinaM., Ersilia V.E.V. Fiscarelli Ersilia V.E.V., PaolaP. Rosati PaolaP., Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Pseudomonas aeruginosa in Cystic Fibrosis. An Argumentative Review, „Frontiers in Microbiology”, 9, 2018, s. 775, DOI: 10.3389/fmicb.2018.00775, PMID: 29780361, PMCID: PMC5945972 .
StephanieS. Trend StephanieS. i inni, Use of a Primary Epithelial Cell Screening Tool to Investigate Phage Therapy in Cystic Fibrosis, „Frontiers in Pharmacology”, 9, 2018, s. 1330, DOI: 10.3389/fphar.2018.01330, PMID: 30546305, PMCID: PMC6280614 .

web.archive.org

ESHRE: Guidelines for FISH-based PGD. [dostęp 2021-07-05]. [zarchiwizowane z tego adresu (2012-04-02)].

worldcat.org

Steven M. Rowe, J.P. Clancy, Eric J. Sorscher. Głęboki oddech. „Świat Nauki”. nr. 9 (241), s. 51–53, wrzesień 2011. Prószyński Media. ISSN 0867-6380.